French healthcare company Sanofi SA (Euronext Paris:SAN) (Nasdaq:SNY) said on Friday that Dupixent (dupilumab) has been recommended by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for expanded approval in the European Union to treat children as young as six months old with severe atopic dermatitis.
Dupixent is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways and is not an immunosuppressant. It is being jointly developed by Sanofi and Regeneron Pharmaceuticals Inc (Nasdaq:REGN) under a global collaboration agreement.
The CHMP recommendation is based on a Phase 3 trial in children aged six months to five years, showing that Dupixent improved skin clearance, reduced overall disease severity and improved health-related quality of life.
Dupixent has received regulatory approvals in countries around the world for use in certain patients with atopic dermatitis, prurigo nodularis, asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP) or eosinophilic esophagitis (EoE) in different age populations. Dupixent is currently approved for one or more of these indications in over 60 countries, including in Europe, the United States and Japan.
Diamyd Medical secures Eurasian patent for insulin-based antigen therapy in type 1 diabetes
Sobi's Biologics License Application for NASP in uncontrolled gout accepted by FDA
Hydrosome Labs announces promising fermentation breakthrough with ultrafine bubbles
Ionis receives FDA Breakthrough Therapy designation for ION582 in Angelman syndrome
AMO Pharma signs licence agreement with PHRI and Venca Research Inc to advance new study in ARVC
Saol Therapeutics receives US FDA Complete Response Letter for SL1009 (DCA) in PDCD
Amgen and Kyowa Kirin release rocatinlimab study results in atopic dermatitis
Hemogenyx Pharmaceuticals partners with Made Scientific to advance CAR-T therapy